8 research outputs found
1-Year Relative Conditional Survival by Time Period.
<p>1-Year Relative Conditional Survival by Time Period.</p
Stepwise inclusion and exclusion of patients with urothelial carcinoma included in the SEER database from 1990–2010.
<p>Stepwise inclusion and exclusion of patients with urothelial carcinoma included in the SEER database from 1990–2010.</p
1 year relative conditional survival by time period.
<p>1 year relative conditional survival by time period.</p
Proportion of patients defined as cisplatin-ineligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation (n = 126).
<p>Proportion of patients defined as cisplatin-ineligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation (n = 126).</p
Surgical outcomes and pathologic findings of patients with MIBC who received radical cystectomy.
<p>Subgroups are based on (1) receipt or non-receipt of neoadjuvant cisplatin-based chemotherapy and (2) CrCl (above or below 60) based on the Cockroft-Gault (CG) equation.</p
Proportion of patients defined as cisplatin-eligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation in subsets based on age (a), race (b) and comorbidity (c).
<p>Proportion of patients defined as cisplatin-eligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation in subsets based on age (a), race (b) and comorbidity (c).</p
Demographic and clinicopathologic characteristics, as well as selected clinical outcomes, of patients with MIBC who received radical cystectomy.
<p>Subgroups are based on (1) receipt or non-receipt of neoadjuvant cisplatin-based chemotherapy and (2) CrCl (above or below 60) based on the Cockroft-Gault (CG) equation.</p